SCHEMBL2909578

SCHEMBL2909578

COC(=O)c1ccc2c(=O)n(-c3ncc(Cl)cc3Cl)c(=S)[nH]c2c1

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 0.62
▸ KMT2A Q03164 5/20 0.62
▸ SMN1; SMN2 Q16637 4/20 0.62
▸ MEN1 O00255 4/20 0.62
▸ KDM4E B2RXH2 6/20 0.59
▸ POLB P06746 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ PKM P14618 1/20 0.54
▸ HPGD P15428 3/20 0.49
▸ HTT P42858 1/20 0.49
▸ TDP1 Q9NUW8 1/20 0.49
▸ MAPT P10636 1/20 0.48
▸ ALOX12 P18054 1/20 0.48
▸ MAPK1 P28482 1/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.46
▸ ESR1 P03372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2900654 0.87 KDM4E (0.64) ALDH1A1KMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL2909181 0.82 ALDH1A1 (0.67) ALDH1A1KMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL2895330 0.79 MEN1 (0.53) ALDH1A1KMT2ASMN1; SMN2MEN1POLB
SCHEMBL2731359 0.74 KMT2A (0.70) ALDH1A1KMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL2117997 0.73 ALDH1A1 (0.62) ALDH1A1KMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL2909354 0.73 KDM4E (0.66) ALDH1A1KMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL2730985 0.72 KMT2A (0.67) ALDH1A1KMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL2895325 0.72 USP2 (0.64) ALDH1A1KMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL13037514 0.70 ALDH1A1 (0.58) ALDH1A1KMT2ASMN1; SMN2MEN1KDM4E
SCHEMBL11798445 0.69 ALDH1A1 (0.67) ALDH1A1KMT2ASMN1; SMN2MEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298324-A1 Prolyl Hydroxylase Inhibitors SMITH KLINE BEECHAM CORPORATION (US) 2010-11-25 — — US disclosed
EP-2240178-A1 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-10-20 — — EP disclosed
WO-2009086044-A1 PROLYL HYDROXYLASE INHIBITORS SMITH KLINE BEECHAM CORPORATION (US) 2009-07-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298324-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 ALDH1A1 204/4885KMT2A 395/4885SMN1; SMN2 4048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback